Pertuzumab (Perjeta) in Scotland – make your voice heard

Pertuzumab (Perjeta) in Scotland – make your voice heard

Earlier this week, we posted about the current assessment of Kadcyla (trastuzumab emtansine) by the Scottish Medicines Consortium (SMC). 

The SMC are currently also in the process of assessing Pertuzumab (Perjeta) for use in the NHS in Scotland. The SMC are inviting submissions from patient groups to feed into this process. The SMC are due to make a decision this October. 

Pertuzumab is used to treat secondary breast cancer and locally advanced breast cancer (breast cancer that has spread to the tissues and lymph nodes around the chest, neck and under the breastbone) that can’t be removed by surgery. It is only offered to people with HER2 positive breast cancer who haven’t received previous targeted therapies or chemotherapy for secondary or locally advanced disease

We’d like to hear from people living with secondary breast cancer in Scotland and their families on the impact having access to this drug could have, both for people with secondary breast cancer and those around them.

Please email to share your views or your story. We will use this for our response and keep you updated.

Many thanks

Emma, The Policy & Campaigns team